Ocaliva (Obeticholic Acid) Patent Expiration, LOE Window & CMS Spending
Ocaliva (Obeticholic Acid) by Intercept: FDA Orange Book core substance LOE 2033-06-17 (last listed 2036-04-26), 0 AB generics, $208.1M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Intercept |
| FDA Application & Pathway | N207999 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2033-06-17 |
| Last Listed Patent or Exclusivity Date | 2036-04-26 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $208.1M |
| 2024 Medicare Part D Spend | $185.0M |
| 2024 Medicaid Spend | $23.1M |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 25.8% 2-yr change) |